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Abstract: Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder closely related
to metabolic syndrome. NAFLD can progress to an inflammatory state called non-alcoholic
steatohepatitis (NASH), which may result in the development of fibrosis and hepatocellular carcinoma.
To develop therapeutic strategies against NAFLD, a better understanding of the molecular mechanism
is needed. Current in vitro NAFLD models fail to capture the essential interactions between liver
cell types and often do not reflect the pathophysiological status of patients. To overcome limitations
of commonly used in vitro and in vivo models, precision-cut liver slices (PCLSs) were used in
this study. PCLSs, prepared from liver tissue obtained from male Wistar rats, were cultured in
supraphysiological concentrations of glucose, fructose, insulin, and palmitic acid to mimic metabolic
syndrome. Accumulation of lipid droplets was visible and measurable after 24 h in PCLSs incubated
with glucose, fructose, and insulin, both in the presence and absence of palmitic acid. Upregulation
of acetyl-CoA carboxylase 1 and 2, and of sterol responsive element binding protein 1c, suggests
increased de novo lipogenesis in PCLSs cultured under these conditions. Additionally, carnitine
palmitoyltransferase 1 expression was reduced, which indicates impaired fatty acid transport and
disrupted mitochondrial β-oxidation. Thus, steatosis was successfully induced in PCLSs with
modified culture medium. This novel ex vivo NAFLD model could be used to investigate the
multicellular and molecular mechanisms that drive NAFLD development and progression, and to
study potential anti-steatotic drugs.
Keywords: NAFLD; non-alcoholic fatty liver disease; ex vivo; pathophysiological model;
metabolism; steatosis
1. Introduction
Non-alcoholic fatty liver disease (NAFLD), also known as hepatic steatosis, is a condition in
which there is an abnormally high lipid deposition in the liver that is unrelated to excessive alcohol
intake [1,2]. The severity of NAFLD varies, and an estimated 20% of NAFLD patients develop
non-alcoholic steatohepatitis (NASH), [3] which can progress to liver cirrhosis or hepatocellular
carcinoma [1–4]. NAFLD is strongly associated with metabolic syndrome, in particular the metabolic
abnormalities hyperinsulinemia and hyperglycemia [4–9].
The supraphysiological concentrations of insulin and glucose associated with these pathological
conditions induce lipogenic genes through the action of sterol regulatory element binding protein-1c
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(SREBP-1c), and carbohydrate responsive element binding protein (MLXIPL), respectively. SREB-1c
and MLXIPL induce acetyl-CoA carboxylase 1 (ACC1), which is involved in the synthesis of
malonyl-CoA—a substrate for fatty acid synthesis and inhibitor of fatty acid oxidation. This chain of
reactions results in a misbalance of carbohydrate and lipid metabolism [10–12], and instead of oxidizing
lipids, triglyceride esterification and thus de novo lipogenesis (DNL) is increased [13]. For example,
diabetes mellitus is a major co-morbid disease in NAFLD patients [10,11].
Glucose is not the only saccharide that can induce de novo lipogenesis. Fructose has the same
basic properties [14–17], but a big difference is that fructose is mainly metabolized in the liver, whereas
glucose can be metabolized throughout the whole body [16,18]. Therefore, the negative effects of
fructose consumption, which has increased dramatically over the years, will mostly affect the liver [19].
While de novo lipogenesis is a key source of triglycerides, another source are the lipids that
are present in the liver. Hyperlipidemia, an elevated amount of blood lipids, and especially
hypertriglyceridemia, leads to an increased hepatic uptake of lipids and thereby contributes to hepatic
steatosis [7,20].
Besides increased lipid uptake and lipid synthesis, reduced lipolysis and secretion also play
an important role in the accumulation of fat. Under normal circumstances, long-chain fatty acids
are transported from the cytosol to the mitochondrial matrix where they undergo β-oxidation [21].
Transport to the mitochondrial matrix depends on carnitine palmitoyltransferase 1 (CPT1) and carnitine
palmitoyltransferase 2 (CPT2) [22].
Additionally, lipids are directly involved in lipotoxicity [21,23]. The lipotoxicity has been
extensively investigated in vitro using palmitic acid, which is the most abundant saturated fatty
acid in the human body [24–26]. While the molecular mechanism behind palmitate’s ability to induce
lipotoxic reactive oxygen species is not entirely clear, it is assumed that fatty acid oxidation plays an
important role [27]. Lipotoxicity and disruption of mitochondrial β-oxidation are considered the most
harmful factors in NAFLD development and progression [26].
NAFLD can only partly be managed by modifications in diet and lifestyle [28,29]. To date,
the mechanisms underlying NAFLD development and the progression to NASH remain elusive.
Consequently, there are no approved pharmacological interventions for NAFLD or NASH.
Several in vitro models are used to study the pathogenesis of NAFLD [30,31], but these do
not accurately reflect the pathophysiological status of NAFLD patients since many models do not
recapitulate the multicellular nature of the disease [11,32,33]. In the pathogenesis of NAFLD and
related liver diseases, communication between hepatocytes, Kupffer cells, and hepatic stellate cells is
essential [32,33]. The most prominent advantage of precision-cut liver slices (PCLSs) is the preserved
multicellular environment allowing for the interplay between various liver cell types [31,34]. PCLSs
have previously been shown to be a useful model to study multicellular diseases [35,36], and may be a
useful model to study the pathophysiological processes in NAFLD. Therefore, the aim of this study
was to induce liver steatosis in PCLSs, by using culture conditions that reflect metabolic syndrome.
2. Methods
2.1. Animals
Male Wistar rats, aged 12 to 16 weeks, were purchased from Charles River (Sulzfeld, Germany).
Experiments were approved by the Animal Ethical Committee of the University of Groningen.
2.2. Precision-Cut Liver Slices (PCLSs)
PCLSs, with an estimated thickness of 250–300 µm, were prepared using a Krumdieck Tissue
Slicer (Alabama Research and Development, Munford, AL, USA) [37], and cultured under continuous
supply of 80% O2 and 5% CO2, as previously described [36]. PCLSs were cultured up to 48 h and
culture media was refreshed every 24 h.
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2.3. Culture Media
Williams medium E with Glutamax (Invitrogen, Bleiswijk, the Netherlands), supplemented
with gentamycin (50 mg/mL; Invitrogen), was used as control medium. To mimic metabolic
syndrome, supraphysiological concentrations of glucose (Merck, Darmstadt, Germany), fructose
(Merck, Darmstadt, Germany), human insulin (Sigma-Aldrich, St. Louis, MO, USA), and palmitic acid
(Sigma-Aldrich, St. Louis, MO, USA) were added to the medium. The experimental concentrations
(Table 1) were based on human serum concentrations [5–7,11,32,33] and in vivo rodent portal vein
concentrations [38–40].
Table 1. Culture media.
Medium Additives
Final Concentration of Additives
Glucose Fructose Insulin Palmitic Acid
CTR None 11 mM
G Glucose 25 mM
F Fructose 5 mM
GF Glucose and fructose 25 mM 5 mM
GFI Glucose, fructose, and insulin 25 mM 5 mM 1 nM
GFIP Glucose, fructose, insulin, and palmitic acid 25 mM 5 mM 1 nM 240 µM
CTR = control; G = glucose; F = fructose; GF = glucose and fructose; GFI = glucose, fructose and insulin; GFIP =
glucose, fructose, insulin and palmitic acid.
Palmitic acid was solubilized using bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO,
USA). Palmitic acid was briefly dissolved in 0.1 M sodium hydroxide (Merck, Darmstadt, Germany) at
70 ◦C, and then mixed with preheated BSA solution at 55 ◦C. The same concentration of BSA (0.04%),
without palmitic acid, was added to media not containing palmitic acid. This concentration of BSA
had no effect on PCLS viability.
2.4. Oil Red O Staining
Cryosections were prepared by embedding fresh PCLSs in KP-cryocompound (Klinipath, Duiven,
the Netherlands) on dry ice. Tissue sections, 4 µm in thickness, were prepared perpendicular to the
surface of PCLSs. Steatosis was evaluated by staining lipid droplets with Oil Red O. Cryosections were
fixed with 4% formaldehyde/PBS for 10 min before staining with Oil Red O solution (0.6% Oil Red O
in 36% 2-propanol) for 10 min at room temperature. Sections were counterstained with haematoxylin
and fixed with Aquatex (Merck, Darmstadt, Germany). Pictures were taken with a BX41 microscope
(Olympus America Inc, Center Valley, PA, USA, 400× magnification), and analyzed using ImageScope
software (v12.3.2.8013, Aperio, Vista, CA, USA). A ratio of red pixels to blue pixels (lipid droplets per
nucleus) was used to examine the change in fat content. Three PCLSs from each treatment were used
per experiment.
2.5. ATP Determination
Viability was assessed by determining ATP content of the slices using a bioluminescence kit
(Roche Diagnostics, Mannheim, Germany) as previously described [37]. Values for each group were
expressed as relative percentage of the 24 h control.
2.6. Protein Estimation
Total protein content of the slices was estimated using a Lowry assay (BioRad DC Protein
Assay, Hercules, CA, USA). Values were expressed as change in protein content as compared to
the 24 h control.
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2.7. Triglyceride Quantitation
PCLSs were snap-frozen and stored at −80 ◦C. Subsequently, the slices were homogenized in
Tris-buffered saline. Fat was isolated using the Bligh & Dyer method [41]. The amount of triglycerides
was determined using a Trig/GB kit (Roche Molecular Biochemicals, Almere, the Netherlands)
according to the protocol provided by the manufacturer. Values were calculated using the absorption at
540 nm after one hour, and are displayed as the change in percentage as compared to the control (CTR).
2.8. Quantitative Real-Time PCR
Expression of key genes in carbohydrate and lipid metabolism was assessed using quantitative
real-time PCR. For each experiment, three slices were pooled per condition, snap-frozen in liquid
nitrogen, and stored at −80 ◦C. RNA was isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen,
Venlo, the Netherlands). The Reverse Transcription System (Promega, Leiden, the Netherlands) was
used to reverse transcribe RNA. Expression of genes related to metabolism, inflammation, and ER
stress was determined using TaqMan primers and probes and SYBR Green primers, the sequences of
which can be found in Table S1, Supplementary Materials (ThermoFisher Scientific, Waltham, MA,
USA). Quantitative real-time PCR was performed using a VIIA7 thermal cycling system (Applied
Biosystems, Carlsbad, CA, USA). For TaqMan primers and probes, the 1X FastStart Universal Probe
Master (Roche, Almere, the Netherlands) was used. The thermal cycling conditions were one cycle at
95 ◦C for 10 min, followed by 45 cycles starting with 95 ◦C for 15 s, then 60 ◦C for 30 s, and ending with
72 ◦C for 30 s. For SYBR Green primers, the FastStart Universal Sybr Green Master (Roche, Almere,
The Netherlands) was used. On the VIIA7 thermal cycling system, the process started with a 10 min
hold at 95 ◦C, followed by 40 cycles that consisted of 15 s at 95 ◦C, 30 s at 60 ◦C, and 30 s at 72 ◦C.
Ct values were corrected for the Ct values of Ywhaz (∆Ct) and compared to control (∆∆Ct). Results are
displayed as fold induction (2−∆∆Ct).
2.9. Statistics
For each liver, three PCLSs were used per condition. Each experiment was performed at least
three times. Results are expressed as means ± standard error of the mean (SEM) and compared to the
control group, using a one-way ANOVA with Dunnett’s post hoc analysis, unless specified otherwise.
Results were considered statistically significant when the calculated p-value was smaller than 0.05.
3. Results
3.1. PCLS Characteristics
PCLSs remained viable, as assessed by ATP content, in all conditions and at all time points
(Figure 1A). In control PCLSs, ATP content was lowered from 100% ± 11% at 24 h of incubation to 66%
± 6% at 48 h. This difference was not statistically significant.
Fructose-containing media (F and GF) seemed to reduce ATP content in PCLSs, especially after
48 h. However, this reduction was not significant. After 48 h, ATP content of slices incubated in
medium GFI was not different from the 48 h control, but addition of palmitic acid resulted in a
significantly increased ATP content.
Figure 1B depicts the changes in protein content of PCLSs, as compared to the 24 h control.
Measured protein levels were higher in PCLSs cultured in the insulin-containing media (GFI and GFIP)
after 24 h, as compared to the 24 h CTR. Protein content of other conditions did not differ from control.
The amount of protein in PCLSs was significantly reduced over time, except for PCLSs in GFI and
GFIP media, which retained increased protein levels after 48 h.
Morphology of PCLSs after 24 and 48 h of incubation in the different media compositions is
shown in Figure 2. There are no clear signs of cellular damage in the form of pyknosis and necrosis
after 24 or 48 h.
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Figure 1. (A) ATP content of precision-cut liver slices (PCLSs) after 24 and 48 h. Data is presented as 
mean percentage of 24 h control ± SEM (n = 5). Using a one-way ANOVA, all conditions were 
compared to the relative control. * p < 0.05 (B) Difference in protein content after 24 and 48 h. Data is 
expressed as mean difference as compared to the 24 h control ± SEM (N = 5). Significance was 
determined using a one-way ANOVA, comparing all conditions from a time point to the control of 
that time point. * p < 0.05, ** p < 0.01, *** p < 0.001. CTR = control, G = Glucose, F = Fructose, GF = 
Glucose and fructose, GFI = Glucose, fructose, and insulin, GFIP = Glucose, fructose, insulin, and 
palmitic acid. 
3.2. Hepatic Steatosis in PCLSs 
Steatosis was evaluated microscopically in PCLSs using an Oil Red O staining. As shown in 
Figure 2A, few lipid-rich droplets were visible after 24 h of incubation in media that contained 
glucose (G), fructose (F), and glucose and fructose (GF). In contrast, an abundance of small-size lipid 
droplets was seen in PCLSs cultured in media containing glucose, fructose, and insulin (GFI) as well 
as in glucose, fructose, insulin, and palmitic acid (GFIP). After 48 h, the pattern of steatosis was 
similar. No lipid droplets were observed in PCLS cultured in media that contained glucose, fructose 
and palmitic acid (supplementary Figure S1).    
In order to confirm the microscopic evaluation, liver steatosis was quantified using a fat-to-
nucleus ratio calculation. From the 24 h- to the 48 h-time point, the fat-to-nucleus ratio did not 
increase in control PCLSs (Figure S2, Supplementary Materials). Figure 2B shows that when 
compared to control, culturing in medium GFI and in medium GFIP for 24 h resulted in a 20% 
increase of fat per nucleus. After 48 h, in comparison to the 48 h control, the amount of fat droplets 
per nucleus increased 15% for both GFI and GFIP.  
Figure 2C shows the level of triglycerides that were measured in PCLSs, as a difference in 
percentage of the 24 h control. For conditions G, F, and GF, no difference in the content of triglycerides 
could be determined at either time point when comparing to control PCLSs. After 24 h and 48 h, the 
triglyceride content was significantly increased in PCLSs cultured in medium containing saccharides 
and insulin, both in the absence and presence of palmitic acid (34% and 27%, respectively, after 24 h, 
and 52% and 38% after 48 h).  
Figure 1. (A) ATP content of precision-cut liver slices (PCLSs) after 24 and 48 h. Data is presented
as mean percentage of 24 h control ± SEM (n = 5). Using a one-way ANOVA, all conditions were
compared to the relative control. * p < 0.05 (B) Difference in protein content after 24 and 48 h. Data
is expressed as mean difference as compared to the 24 h control ± SEM (N = 5). Significance was
determined using a one-way ANOVA, comparing all conditions from a time point to the control of that
time point. * p < 0.05, ** p < 0.01, *** p < 0.001. CTR = control, G = Glucose, F = Fructose, GF = Glucose
and fructose, GFI = Glucose, fructose, and insulin, GFIP = Glucose, fructose, insulin, and palmitic acid.
3.2. Hepatic Steatosis in PCLSs
Steatosis was evaluated microscopically in PCLSs using an Oil Red O staining. As shown in
Figur 2A, few lipid-rich droplets were visible after 24 h of incubation in media that contained glucose
(G), fructose (F), and glucose and fructose (GF). In contrast, an abundance of small-size lipid droplets
was seen in PCLSs cultured in media containing glucose, fructose, and insulin (GFI) as well as in
glucose, fructose, insulin, and palmitic acid (GFIP). After 48 h, the pattern of steatosis was similar.
No lipid droplets were observed in PCLS cultured in media that contained glucose, fructose and
palmitic acid (Supplementary Figure S1).
In order to confirm the microscopic evaluation, liver steatosis was quantified using a fat-to-nucleus
ratio calculation. From the 24 h- to the 48 h-time point, the fat-to-nucleus ratio did not increase in
control PCLSs (Figure S2, Supplementary Materials). Figure 2B shows that when compared to control,
culturing in medium GFI and in medium GFIP for 24 h resulted in a 20% increase of fat per nucleus.
After 48 h, in comparison to the 48 h control, the amount of fat droplets per nucleus increased 15% for
both GFI and GFIP.
Figure 2C shows the level of triglycerides that were measured in PCLSs, as a difference in
percentage of the 24 h control. For conditions G, F, and GF, no difference in the content of triglycerides
could be determined at either time point when comparing to control PCLSs. After 24 h and
48 h, the triglyceride content was significantly increased in PCLSs cultured in medium containing
saccharides and insulin, both in the absence and presence of palmitic acid (34% and 27%, respectively,
after 24 h, and 52% and 38% after 48 h).
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Figure 2. (A) Representative Oil Red O stained PCLS sections, cultured in different culture media, for 
24 h and 48 h. CTR = control, G = Glucose, F = Fructose, GF = Glucose and fructose, GFI = Glucose, 
fructose, and insulin, GFIP = Glucose, fructose, insulin, and palmitic acid. (B) Fat-to-nucleus ratio. Oil 
Red O stained sections were used to determine the ratio of fat droplets per nucleus. Data is shown as 
the mean change in percentage of the ratio ± SEM (N = 4). (C) Difference in measured triglyceride 
content after 24 h and 48 h. Data is expressed as mean difference in percentages of the 24 h untreated 
control ± SEM (n = 5–6). Significance was determined using a one-way ANOVA, comparing all 
conditions from a time point to the control of that time point. * = p-value < 0.05, ** = p-value < 0.01, *** 
= p-value < 0.001. 
3.3. Lipid Metabolism 
To investigate whether the accumulation of lipid droplets (Figure 2) was a consequence of 
culture medium modifications, metabolic processes were further investigated by determining gene-
expression genes related to lipid metabolism. Culturing PCLSs in different media had no significant 
effects on the RNA yield (data not shown). Figure 3 shows the relative fold induction of genes 
involved in lipid metabolism, as compared to the 24 h and 48 h control, respectively. Sterol regulatory 
element binding protein 1c (Srebf1) expression was only increased after 24 h in PCLSs cultured in GFI 
and GFIP medium, as seen in Figure 3A. An increased acetyl-CoA carboxylase 1 (Acaca) and acetyl-
CoA carboxylase 2 (Acacb) fold induction is seen in Figure 3B,C. This increase was significant for the 
groups GFI and GFIP after 24 h. The effect on Acaca was no longer visible after 48 h, but the Acacb 
fold induction remained higher. Over time, Acaca expression remained constant and Acacb gene 
expression increased 3.8-fold in control PCLSs, as is seen in Figure S3, Supplementary Materials. The 
first 24 h carbohydrate responsive element binding protein (Mlxipl) fold induction seemed to be 
upregulated by the different culture media, however, not significantly. After 48 h, no upregulation 
was observed (Figure 3D). 
Figure 3E,F shows that carnitine palmitoyltransferase 1 (Cpt1) expression is lower for PCLSs 
cultured in GFI and GFIP medium, both after 24 and 48 h. This in contrast to carnitine 
palmitoyltransferase 2 (Cpt2) expression, which was significantly increased under the same 
conditions.  
None of the media influenced sterol regulatory element binding protein 2 (Srebf2) expression 
(Figure 3G).  
Figure 2. (A) Representative Oil Red O stained PCLS sections, cultured in different culture media, for
24 h and 48 h. CTR = control, G = Glucose, F = Fructose, GF = Gl cose and fructose, GFI = Glucose,
fructose, and insulin, GFIP = Glucose, fructose, ins lin, and palmitic acid. (B) Fat-t -nucleus ratio. Oil
Red O stained sectio s were used t determine the ratio of fat droplets per nucleus. Data is shown as the
m an chang in percentag of the ratio ± SEM (N = 4). (C) Difference in meas red triglyceride content
aft r 24 h and 48 h. Data is expr ssed as mean difference in percentages of the 24 h untreated control ±
SEM ( = 5–6). Significance was determined using a one-way ANOVA, comp ring all conditions from a
time point to the control of that time point. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001.
3.3. Lipid Metabolism
To investigate whether the accumulation of lipid droplets (Figure 2) was a consequence of culture
medium modifications, metabolic processes were further investigated by determining gene-expression
genes related to lipid metabolism. Culturing PCLSs in different media had no significant effects on
the RNA yield (data not shown). Figure 3 shows the relative fold induction of genes involved in lipid
metabolism, as compared to the 24 h and 48 h control, respectively. Sterol regulatory element binding
protein 1c (Srebf1) expression was only increased after 24 h in PCLSs cultured in GFI and GFIP medium,
as seen in Figure 3A. An increased acetyl-CoA carboxylase 1 (Acaca) and acetyl-CoA carboxylase 2
(Acacb) fold induction is seen in Figure 3B,C. This increase was significant for the groups GFI and GFIP
after 24 h. The effect on Acaca was no longer visible after 48 h, but the Acacb fold induction remained
higher. Over time, Acaca expression remained constant and Acacb gene expression increased 3.8-fold in
control PCLSs, as is seen in Figure S3, Supplementary Materials. The first 24 h carbohydrate responsive
element binding protein (Mlxipl) fold induction seemed to be upregulated by the different culture
media, however, not significantly. After 48 h, no upregulation was observed (Figure 3D).
Figure 3E,F shows that carnitine palmitoyltransferase 1 (Cpt1) expression is lower for PCLSs
cultured in GFI and GFIP medium, both after 24 and 48 h. This in contrast to carnitine
palmitoyltransferase 2 (Cpt2) expression, which was significantly increased under the same conditions.
None of the media influenced sterol regulatory element binding protein 2 (Srebf2) expression
(Figure 3G).
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Figure 3. Relative mRNA expression of genes related to lipid metabolism, specifically (A) Srebf1, (B) 
Acaca, (C) Acacb, (D) Mlxipl, (E) Cpt1, (F) Cpt2, and (G) Srebf2. Values are displayed as mean fold 
induction ± SEM (n = 3). Significance was determined using a one-way ANOVA comparing conditions 
to the 24 h or 48 h control, respectively. * = p-value < 0.05, ** = p-value < 0.01, ns = p-value > 0.05. G = 
Glucose, F = Fructose, GF = Glucose and fructose, GFI = Glucose, fructose, and insulin, GFIP = Glucose, 
fructose, insulin, and palmitic acid. 
3.4. Inflammation, Endoplasmic Reticulum Stress, and Fibrosis in PCLSs 
To investigate the effects of the different culture media on the inflammatory responses of PCLSs, 
the expression of interleukin-6 (Il6), transforming growth factor beta (Tgfb), and tumor necrosis 
factor-alpha (Tnf) was determined (Figure 4). Over time, Il6 and Tnf expression increased in PCLSs. 
Tgfb expression remained constant. While no difference could be seen in Il6 expression between slices 
cultured in different media, both Tgfb and Tnf expression seemed to be reduced in the conditions GFI 
and GFIP. These changes were not significant. 
Heat shock protein family A member 5 (Hspa5), more commonly referred to as GRP78/BiP, 
expression was measured to get an indication of endoplasmic reticulum (ER) stress caused by the 
different media. The expression of Hspa5 increased significantly over time in control PCLSs, as 
depicted in Figure S4, Supplementary Materials. Figure 4D shows a significant reduction of Hspa5 
expression after 24 h incubation in media GF, GFI, and GFIP as compared to CTR. After 48 h, no 
differences were seen. 
To see whether the fat accumulation due to the studied media could already induce a fibrotic 
response in PCLSs, the expression of actin, alpha 2, smooth muscle, aorta (Acta2) and collagen type I 
alpha 1 chain (Col1a1) was examined. No different gene expression was observed for either gene in 
PCLSs cultured in different media, as is shown in Figure 4E,F.  
Figure 3. Relative mRNA expression of genes related to lipid metabolism, specifically (A) Srebf1,
(B) Acaca, (C) Acacb, (D) Mlxipl, (E) Cpt1, (F) Cpt2, and (G) Srebf2. Values are displayed as mean fold
induction ± SEM (n = 3). Significance was determined using a one-way ANOVA comparing conditions
to the 24 h or 48 h control, respectively. * = p-value < 0.05, ** = p-value < 0.01, ns = p-value > 0.05.
G = Glucose, F = Fructose, GF = Glucose and fructose, GFI = Glucose, fructose, and insulin, GFIP =
Glucose, fructose, insulin, and palmitic acid.
3.4. Inflammation, Endoplasmic Reticulum Stress, and Fibrosis in PCLSs
To investigate the effects of the different culture media on the inflammatory responses of PCLSs,
the expression of interleukin-6 (Il6), transforming growth factor beta (Tgfb), and tumor necrosis
factor-alpha (Tnf ) was determined (Figure 4). Over time, Il6 and Tnf expression i creased in PCLSs.
Tgfb expression remained constant. While no difference could be seen in Il6 expression between slices
cultured in different media, both Tgfb and Tnf expression seemed to be reduced in the conditio s GFI
and GFIP. These changes were not significant.
Heat shock protein family A member 5 (Hspa5), more commonly referred to as GRP78/BiP,
expression was measured to get an indication of endoplasmic reticulum (ER) stress caused by the
different media. The expression of Hspa5 increased significantly over time in control PCLSs, as epicted
in Figure S4, Supplementary Materials. Figure 4D shows a significant reduction of Hspa5 expression
after 24 h incubation in media GF, GFI, and GFIP as compared to CTR. After 48 h, no differences
were seen.
To see hether the fat accumulation due to the studied media could already induce a fibrotic
response in PCLSs, the expression of actin, alpha 2, smooth muscle, aorta (Acta2) and collagen type I
alpha 1 chain (Col1a1) was examined. No different gene expression was observed for either gene in
PCLSs cultured in different media, as is shown in Figure 4E,F.
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Figure 4. Expression of mRNA related to inflammation, endoplasmic reticulum stress, and fibrosis. 
Expression of genes responsible for inflammation, (A) Il6, (B) Tgfb1, and (C) Tnf, for endoplasmic 
reticulum stress, (D) Hspa5, and for fibrosis, (E) Col1a1 and (F) Acta2, is expressed as mean relative 
fold induction ± SEM (n = 3). A one-way ANOVA comparing conditions to their respective control 
was used to determine significance. CTR = control, G = Glucose, F = Fructose, GF = Glucose and 
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4. Discussion
The burden of NAFLD for patients and society is high, and the mechanism of NAFLD
development remains elusive. One of the problems is the lack of good in vitro models to study
this disease, as ny models do not contain th different cell types that drive pathogene is [32,33].
In PCLSs, the different cell types are present in th ir physiological environment [31,34], which has
been ben ficial in studies on d ug metabolism, drug t xicity, and fibrosis [35–37,42]. In this study,
steatos s wa successfully induced in PCLSs derived from rat liver tissue.
The biggest risk factors for NAFLD a e those rela ed to metabolic syndrome, in particular
hyperglycemia, dyslipidemia, and hyperinsulinemia [5–7,10–12]. Theref re, glucose, fructose, ins in,
and palmitic ci were selected as supplements for the NAFLD–PCLS culture. As the absolute
pathophysiological portal concentration range of these supplements in NAFLD patients is unknown,
supraphysiol gical concentrations based on pathophysiological serum conce trations in NAFLD
patients [11,32,33], and previously measured rodent portal concentrations [38–40], were used.
Mor hological evaluatio and ATP content how that PCLSs remai viable in every condition.
After 48 h, only a small reduction in ATP content was seen for PCLSs that were cultured in
fructose-containing medi . This reduction could be explained by active fructose phosph rylation,
which has no feedb ck loop and only ends when eith r ructose or ATP is depleted [43]. As no
reductio of RNA or protein ontent was observed, the reduction of ATP did not seem t be a problem
f r PCLSs. The reducti in total protein content over time is a normal phenomeno in PCLSs [44].
The increased pr tein content of PCLSs cultured in media that contain insulin suggests that insulin
promotes protein synthesis and possibly reduces p otein catabolism, which i in line with other
studies [45,46]. Additionally, protein synthesis could be increa ed due to the endoplasmic reticulum
(ER) stress pr ent in PCLSs [47].
In contrast to other in vitro stu ies, palmitic acid did not impact PLCS viability. The main
toxic effect of palmitic acid in obese and insulin-resistant individuals is impaired ATP synthesis [27].
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This toxicity has been observed in vitro as well, and is caused by palmitate-induced mitochondrial
dysfunction [24–26]. There are several possible explanations for the absence of lipotoxicity in our model.
First, the antioxidant glutathione is lacking in many in vitro models, but present in PCLSs [48,49].
Glutathione in PCLSs might be able to counteract palmitic acid-induced reactive oxygen species.
Additionally, the concentration of palmitic acid in this model might have been too low to cause
mitochondrial dysfunction, and was used for cellular energy production (as was found after 48 h in
the slices) [27].
The amount of steatosis that resulted from culturing in different media was determined by means
of Oil Red O staining and triglyceride measurement. In the absence of insulin, no steatosis occurs
in PCLSs regardless of other medium components. This indicates that exogenous insulin promotes
the formation and accumulation of lipid droplets in this pathophysiological PCLS model, which is
in line with other studies [50]. This could be caused by insulin-dependent de novo lipogenesis and
Srebf1 processing [50]. The unaltered Srebf2 gene expression in the PCLSs indicates that there was no
additional cholesterol formation in PCLSs and that lipid droplets therefore most likely consisted of
triglycerides [11].
The lipid droplets that accumulated in PCLSs in this study can be characterized as microvesicular
steatosis. This is in line with other in vitro NAFLD studies [51–53], but differs from the macrovesicular
steatosis found in various in vivo models of NAFLD [30]. A possible explanation for the size difference
in lipid droplets between the models is the difference in the duration of steatosis induction. For in vivo
studies, this timeframe comprises months, while in vitro studies are generally limited to several days.
In shorter in vivo studies, microvesicular lipid droplets have been observed [54].
In this early onset of steatosis, another factor is the different manner of lipid droplet formation,
which may be caused by either reduced mitochondrial β-oxidation or de novo lipogenesis [21].
In this study, gene expression of Srebf1 and Mlxipl and gene expression of their target genes Acaca
and Acacb [11] were used as a measure of de novo lipogenesis. All the aforementioned genes were
upregulated in PCLSs where onset of steatosis was observed. While protein expression for these genes
was not determined, it has been shown that increased mRNA expression of de novo lipogenesis genes
was related to increased protein expression of these genes [55–57].
Previous studies have shown that impaired mitochondrial β-oxidation might be the cause of
microvesicular steatosis in vivo [10,58]. To find out whether mitochondrial β-oxidation plays a role
in steatosis in PCLSs, Cpt1 mRNA expression was examined. CPT1 transports fatty acids from the
cytosol to mitochondria, and thereby catalyzes the rate-limiting step of fatty acid oxidation [11]. CPT1
is inhibited by the substrate that the acetyl-CoA carboxylases (ACC) produce. In line with increased
Acc gene expression, a reduction in Cpt1 gene expression was found. This phenomenon has been
observed in in vivo and in vitro studies [10,11]. Cpt2 expression was not downregulated as CPT2 is
not inhibited by the substrate produced by ACC. Increased CPT2 levels have previously been linked
to stress, which could also be the case in PCLSs [59].
These results indicate that both increased lipid synthesis and reduced lipid breakdown are
connected to the steatosis in this PCLS model, which is in line with in vivo studies [22]. Furthermore,
the results support the idea that acetyl-CoA 1 and 2 inhibition might be an interesting target to halt de
novo lipogenesis [60].
In this study, changes in the expression of Hspa5, also known as glucose-regulated protein,
78kDa/binding-immunoglobulin protein (GRP78/BiP), were observed. HSPA5 is the master regulator
of endoplasmic reticulum (ER) homeostasis and interacts with the three major unfolded protein
response (UPR) branches, which have direct effects on lipid synthesis [61,62]. Over time, expression of
Hspa5 increased in control PCLSs. HSPA5 gene expression is linked to HSPA5 protein expression [63],
and is induced in response to ER stress [62]; these results indicate that PCLS preparation or culturing
leads to ER stress. Increased HSPA5 expression has been shown to protect against hepatic steatosis,
whereas HSPA5 loss induces it [62,64]. Additionally, loss of HSPA5 induces phosphorylation of c-Jun
N-terminal kinases (JNK), which has been linked to NASH [65]. Upon measuring Hspa5 in PCLSs,
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a significant reduction was found when culturing in medium containing sugars, insulin, and fat. While
the exact relationship between UPR signaling and lipogenesis is unknown [66], the decrease might be
linked to increased Acaca expression [65] and increased Srebf1 expression [67], both of which were also
observed in PCLSs. As the HSPA5 decrease in PCLSs is in line with observations in NAFLD/NASH
patients [68,69], it might be interesting to study the relation between ER stress, UPR, and fatty liver
disease in this PCLS model.
NAFLD has different stages, the first being fatty liver. This stage is characterized by a certain
amount of steatosis and an absence of inflammation or fibrosis. A percentage of patients in this first
stage will develop the more harmful condition non-alcoholic steatohepatitis, which is characterized
by inflammation of fatty liver tissue. In this study, steatosis was observed but no inflammation or
fibrosis was measured on a gene level. Therefore, one of the next steps in NAFLD–PCLS is to induce
inflammation. Since it is possible in this PCLS model to control which factors are present and in which
order, it could be used to gain more insight into NAFLD development and progression. For example,
the model could be used to clarify whether there is a specific order in which inflammation and steatosis
drive NAFLD/NASH progression, or whether they work side by side [5,23].
5. Conclusions
In conclusion, microvesicular steatosis was induced in precision-cut liver slices by mimicking
the NAFLD risk factors. Gene expression data suggest that early steatosis was achieved through both
de novo lipogenesis and reduced mitochondrial β-oxidation. While gene expression indicated the
presence of ER stress, the culture media did not have a negative effect on PCLS viability, or induce
an inflammatory or fibrotic response. More studies are needed to determine whether a proper
pathophysiological NAFLD–PCLS model was developed, and the limitations of this PCLS model,
such as the short incubation time and the absence of inter-tissue communication, should be taken into
account. Precision-cut liver slices derived from human tissue would even better enable extrapolation to
the situation in humans. This PCLS model may be pivotal in investigating the multicellular molecular
mechanisms behind NAFLD development and progression to NASH, and in studying potential
anti-steatotic drugs. Additionally, the model could be used to investigate drug-induced hepatic
steatosis, as both micro- and macrovesicular steatosis have been observed after in vitro and in vivo
exposure to drugs such as glucocorticoids and antimicrobials [70].
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